Showing results (271-280 of 468) with videos related to

Sort By:
Pageof 47
The Journal of Urology|May 28, 2013
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO GuidelineIan M Thompson, Richard K Valicenti, Peter Albertsen, et al.
The Journal of Urology|January 15, 2013
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculatorDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
The Journal of Urology|October 20, 2009
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionStephen J Eyre, Donna P Ankerst, John T Wei, et al.
Cancer Letters|July 14, 2018
Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiationSuleman S Hussain, Shih-Bo Huang, Roble G Bedolla, et al.
Biometrical Journal. Biometrische Zeitschrift|November 19, 2011
Updating risk prediction tools: a case study in prostate cancerDonna P Ankerst, Tim Koniarski, Yuanyuan Liang, et al.
The Journal of Urology|April 20, 2013
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinEila C Skinner, Bryan Goldman, Wael A Sakr, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2025
Emerging Strategies for Drug-Based Cancer Risk ReductionMaria Daca-Álvarez, Angelo Brunori, Alessio Carbone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
World Journal of Urology|November 17, 2010
Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methodsIan M Thompson, Shady Salem, Sam S Chang, et al.
Urologic Oncology|May 11, 2010
Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancerXiao-Jian Qin, Chun-Guang Ma, Ding-Wei Ye, et al.
Pageof 47